Balyasny Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.9M | Sell |
40,137
-73,351
| -65% | -$34.2M | 0.02% | 733 |
|
|
2025
Q4 | $51.5M | Buy |
+113,488
| New | +$48.9M | 0.07% | 348 |
|
|
2025
Q2 | – | Sell |
-2,264
| Closed | -$1.04M | – | 3399 |
|
|
2025
Q1 | $1.1M | Sell |
2,264
-133,559
| -98% | -$62.2M | ﹤0.01% | 1950 |
|
|
2024
Q4 | $54.7M | Buy |
135,823
+81,351
| +149% | +$37.7M | 0.08% | 300 |
|
|
2024
Q3 | $25.3M | Buy |
54,472
+52,180
| +2,277% | +$25.1M | 0.04% | 548 |
|
|
2024
Q2 | $1.07M | Sell |
2,292
-185,844
| -99% | -$80.7M | ﹤0.01% | 1761 |
|
|
2024
Q1 | $78.6M | Buy |
188,136
+183,380
| +3,856% | +$77.5M | 0.14% | 172 |
|
|
2023
Q4 | $1.94M | Buy |
4,756
+873
| +22% | +$323K | ﹤0.01% | 1465 |
|
|
2023
Q3 | $1.35M | Buy |
3,883
+159
| +4% | +$55.6K | ﹤0.01% | 1490 |
|
|
2023
Q2 | $1.31M | Sell |
3,724
-35,245
| -90% | -$11.9M | ﹤0.01% | 1516 |
|
|
2023
Q1 | $12.3M | Buy |
38,969
+1,148
| +3% | +$344K | 0.03% | 702 |
|
|
2022
Q4 | $10.9M | Buy |
+37,821
| New | +$11.5M | 0.03% | 709 |
|
|
2022
Q2 | – | Sell |
-19,312
| Closed | -$5.17M | – | 3223 |
|
|
2022
Q1 | $5.04M | Sell |
19,312
-192,035
| -91% | -$45.6M | 0.02% | 944 |
|
|
2021
Q4 | $46.4M | Buy |
211,347
+56,709
| +37% | +$11M | 0.16% | 154 |
|
|
2021
Q3 | $28.1M | Buy |
+154,638
| New | +$30.2M | 0.12% | 245 |
|
|
2020
Q3 | – | Sell |
-4,249
| Closed | -$1.23M | – | 1630 |
|
|
2020
Q2 | $1.23M | Buy |
+4,249
| New | +$1.15M | 0.01% | 791 |
|
|
2020
Q1 | – | Sell |
-159,396
| Closed | -$34.9M | – | 1551 |
|
|
2019
Q4 | $34.9M | Buy |
+159,396
| New | +$32.3M | 0.21% | 138 |
|
|
2019
Q3 | – | Sell |
-5,043
| Closed | -$892K | – | 1623 |
|
|
2019
Q2 | $925K | Sell |
5,043
-14,660
| -74% | -$2.56M | 0.01% | 1098 |
|
|
2019
Q1 | $3.62M | Sell |
19,703
-1,675
| -8% | -$309K | 0.02% | 649 |
|
|
2018
Q4 | $3.54M | Buy |
21,378
+5,373
| +34% | +$931K | 0.03% | 572 |
|
|
2018
Q3 | $3.08M | Buy |
+16,005
| New | +$2.85M | 0.01% | 850 |
|
|
2018
Q1 | – | Sell |
-347,312
| Closed | -$52M | – | 2337 |
|
|
2017
Q4 | $52M | Buy |
347,312
+155,682
| +81% | +$23.1M | 0.16% | 156 |
|
|
2017
Q3 | $29.1M | Sell |
191,630
-200,462
| -51% | -$30.2M | 0.11% | 238 |
|
|
2017
Q2 | $50.5M | Buy |
392,092
+126,175
| +47% | +$15.2M | 0.21% | 122 |
|
|
2017
Q1 | $29.1M | Buy |
265,917
+170,261
| +178% | +$15M | 0.14% | 194 |
|
|
2016
Q4 | $7.05M | Buy |
95,656
+5,652
| +6% | +$460K | 0.04% | 593 |
|
|
2016
Q3 | $7.85M | Buy |
90,004
+5,519
| +7% | +$522K | 0.05% | 435 |
|
|
2016
Q2 | $7.27M | Sell |
84,485
-14,225
| -14% | -$1.23M | 0.05% | 432 |
|
|
2016
Q1 | $7.85M | Sell |
98,710
-396,600
| -80% | -$35.9M | 0.05% | 456 |
|
|
2015
Q4 | $62.3M | Buy |
495,310
+426,304
| +618% | +$51.5M | 0.43% | 49 |
|
|
2015
Q3 | $7.19M | Buy |
+69,006
| New | +$8.87M | 0.05% | 431 |
|
|
2013
Q3 | – | Sell |
-55,000
| Closed | -$4.4M | – | 727 |
|
|
2013
Q2 | $4.4M | Buy |
+55,000
| New | +$4.05M | 0.07% | 317 |
|
Other funds holding VRTX
VCM
VPM
Balyasny Asset Management's VRTX Position: Q1 2026 in Review
Balyasny Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 65% in Q1 2026, selling an estimated $34.2M and leaving 40,137 shares worth $17.9M. The position accounts for 0.02% of the portfolio, ranked #733.
Balyasny Asset Management first reported a position in VRTX in Q2 2013 and has held it in 32 quarters since. The position peaked at $78.6M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Balyasny Asset Management held 40,137 shares of Vertex Pharmaceuticals worth $17.9M as of Q1 2026.
- Balyasny Asset Management sold 73,351 Vertex Pharmaceuticals shares in Q1 2026, an estimated $34.2M.
- Vertex Pharmaceuticals made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #733 holding.
- Balyasny Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
- Balyasny Asset Management's Vertex Pharmaceuticals position peaked at $78.6M in Q1 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.